Cryoport, Inc. (CYRX) stock
CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3025% above fair value
$19.80−0.09 (-0.45%)
Close on Nov 16, 2026Market cap $1.00BP/E –Yield –
Cryoport r&d expenses
Research and development expenses are spending on new products and technology.
Cryoport's R&D Expenses for the twelve months ending Sep 30, 2026 was $17.96M, up 7.3% year over year. For fiscal 2025 it was $17.04M, down 3.8% from the year before. Over ten years it grew 45.2% a year on average. The highest annual figure on record is $18.04M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.04M | -3.8% |
| FY2024 | Dec 31, 2024 | $17.71M | -1.8% |
| FY2023 | Dec 31, 2023 | $18.04M | +14.7% |
| FY2022 | Dec 31, 2022 | $15.72M | -6.7% |
| FY2021 | Dec 31, 2021 | $16.84M | +77.6% |
| FY2020 | Dec 31, 2020 | $9.48M | +153.5% |
| FY2019 | Dec 31, 2019 | $3.74M | +103.3% |
| FY2018 | Dec 31, 2018 | $1.84M | +234.5% |
| FY2016 | Mar 31, 2016 | $550.26K | +56.1% |
| FY2015 | Mar 31, 2015 | $352.58K | -13.8% |
| FY2014 | Mar 31, 2014 | $409.11K | -3.8% |
| FY2013 | Mar 31, 2013 | $425.45K | -13.5% |
| FY2012 | Mar 31, 2012 | $491.85K | +9.5% |
| FY2011 | Mar 31, 2011 | $449.13K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $4.73M | +4.7% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $4.85M | +17.8% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $3.91M | -0.7% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $4.47M | +7.5% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $4.52M | +8.8% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $4.12M | -11.4% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $3.93M | -17.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $4.16M | -12.5% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $4.16M | -19.3% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $4.65M | +9.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $4.75M | +22.6% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $4.75M | +1.5% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $5.15M | +29.3% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $4.26M | +21.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $3.88M | +9.6% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $4.68M | +20.2% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $3.99M | -4.8% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $3.52M | -21.1% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $3.54M | -17.8% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $3.89M | +11.4% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $4.19M | +81.1% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $4.46M | +129.2% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $4.30M | +148.4% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $3.49M | +226.5% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $2.31M | +40.9% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $1.95M | +259.9% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $1.73M | +254.0% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $1.07M | +78.7% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $1.64M | +254.0% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $540.93K | +20.6% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $489.60K | +48.5% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $598.76K | +314.4% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $463.36K | +103.4% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $448.59K | +347.3% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $329.73K | +324.2% |
| Q4 FY2016CQ1 2016 | Mar 31, 2016 | $144.48K | +70.0% |
| Q3 FY2016CQ4 2015 | Dec 31, 2015 | $227.77K | – |
| Q2 FY2016CQ3 2015 | Sep 30, 2015 | $100.30K | – |
| Q1 FY2016CQ2 2015 | Jun 30, 2015 | $77.72K | – |
| Q4 FY2015CQ1 2015 | Mar 31, 2015 | $85.01K | – |
See a number that looks wrong?